Skip to main content
main-content

Welcome

We provide news, expert interviews, and educational resources to help you keep up with the latest developments in diabetes

Conference highlights

Browse highlights from the European Association for the Study of Diabetes 58th Annual Meeting.

Initiating GLP-1 receptor agonists: Managing side effects

Specialist nurse Nicola Milne discusses the side effects that can arise in people with type 2 diabetes during initiation of GLP-1 receptor agonists, and how to best manage them.

News

First-line SGLT2 inhibitors, GLP-1 receptor agonists ‘not cost effective’

Researchers calculate that the price of SGLT2 inhibitors and GLP-1 receptor agonists would need to fall “by at least 70%” to make them cost effective first-line treatments in the USA. Read more

New additions to the Adis Journal Club – October update

Browse October's selection of peer-reviewed articles from the Adis journal portfolio. Curated by the editors and updated monthly. These papers highlight topical research and reviews for the benefit of Medicine Matters readers.

Hot topic review

How far has immunotherapy for type 1 diabetes progressed?

Read our Hot Topic Review for a rapid update on the successes and failures of immunotherapies in people with or at high risk for type 1 diabetes.

View from the clinic

Managing hyperglycemia in the face of a high-carbohydrate diet

Sanjay Kalra considers the course of action when blood glucose remains high in someone who cannot, or will not, modify a high-carbohydrate diet. Read more

Content hub

The challenge of type 2 diabetes in children

Who is at the highest risk for developing type 2 diabetes in their youth? What are the consequences of being diagnosed so young, and what can clinicians do to help? Browse the hub to find out

New additions to the Adis Journal Club

A selection of topical peer-reviewed articles from the Adis journals, curated by the editors.

IN FOCUS | GLP-1 receptor agonists

Piggy bank balancing on seesaw over a bottle of pills

10-04-2022 | Healthcare costs | News

First-line SGLT2 inhibitors, GLP-1 receptor agonists ‘not cost effective’

The authors of a modeling study say that the price of SGLT2 inhibitors and GLP-1 receptor agonists would need to fall “by at least 70%” for them to be cost effective as first-line treatments in the USA.

GLP-1 receptor agonists

Browse the latest news, clinical trial updates, and expert commentary.

IN FOCUS | Obesity & lifestyle interventions

Senior women working out using dumbells

08-09-2022 | Older adults | News

Lifestyle intervention strategy beneficial for older adults with diabetes

Lifestyle intervention proves “highly successful” in adults with diabetes aged 65 to 85 years, improving both metabolic and functional health, report researchers.

Semaglutide for weight loss: The STEP and SELECT trials

Get the latest results and insights from the researchers.

IN FOCUS | Pediatric type 2 diabetes

Weekly pill container

04-04-2022 | Dapagliflozin | News

Phase 3 trial supports dapagliflozin in young people with type 2 diabetes

The first phase 3 trial of an SGLT2 inhibitor in children and young people with type 2 diabetes shows that dapagliflozin significantly improves their glucose control – as long as they remember to take it.

The challenge of type 2 diabetes in children

Who is at the highest risk for developing type 2 diabetes in their youth? 

IN FOCUS | Hyperglycemia

X-ray of fractured forearm shaft of radius and ulnar bone on red mark

05-24-2022 | Bone health | News

Poor glycemic control, kidney disease linked to bone fragility in type 1 diabetes

Higher glycated hemoglobin and the presence of kidney disease are associated with lower bone mineral density in people with type 1 diabetes, study results show.

Supporting people with diabetes during Ramadan

Evidence overview and practical advice for fasting with type 1 or type 2 diabetes

IN FOCUS | Cardiovascular disorders

Piggy bank balancing on seesaw over a bottle of pills

10-04-2022 | Healthcare costs | News

First-line SGLT2 inhibitors, GLP-1 receptor agonists ‘not cost effective’

The authors of a modeling study say that the price of SGLT2 inhibitors and GLP-1 receptor agonists would need to fall “by at least 70%” for them to be cost effective as first-line treatments in the USA.

IN FOCUS | Hypoglycemia

White plate with spoon and fork in clock formation, fasting concept

03-31-2022 | Diet | Hot topic review | Article

Fasting and people with diabetes

Read this Hot Topic Review to catch up on the latest research into the risks and benefits of fasting for people with diabetes.

IN FOCUS | Tirzepatide

Person standing on weigh scales with tape measure in foreground

06-04-2022 | ADA 2022 | Conference coverage | News

​​​​​​​SURMOUNT-1 places tirzepatide weight loss efficacy within surgical range

A weekly injection of tirzepatide results in a substantial bodyweight reduction over and above that achieved with lifestyle intervention in people with obesity, show the SURMOUNT-1 findings.

The SURPASS trials

Get the latest reporting, researcher interviews, and independent commentary on tirzepatide for type 2 diabetes.

IN FOCUS | Kidney disease

Guidelines

06-07-2022 | ADA 2022 | Conference coverage | News

​​​​​​​ADA/KDIGO consensus: ‘Speaking the same language’ on CKD management

The ADA and KDIGO have produced a consensus statement on treating chronic kidney disease in people with diabetes.

IN FOCUS | SGLT2 inhibitors

Piggy bank balancing on seesaw over a bottle of pills

10-04-2022 | Healthcare costs | News

First-line SGLT2 inhibitors, GLP-1 receptor agonists ‘not cost effective’

The authors of a modeling study say that the price of SGLT2 inhibitors and GLP-1 receptor agonists would need to fall “by at least 70%” for them to be cost effective as first-line treatments in the USA.

Stay informed with Medicine Matters

Get the latest developments in diabetes delivered straight to your inbox

Addressing suicide risk in diabetes

Learn about rates and risk, underlying psychological factors, and practical actions to support patients.

IN FOCUS | Mental health & psychosocial care

Lori Berard

04-14-2022 | Hyperglycemia | View from the clinic | Article

Managing hyperglycemia related to stress

Lori Berard highlights the contribution of stress to poor glycemic control and considers how healthcare providers can account for this in their practice.

IN FOCUS | Diabetes devices & technology

Girl with CGM

09-21-2022 | EASD 2022 | Conference coverage | News

Skin reactions rarely lead to diabetes device discontinuation

Skin reactions to glucose monitors and insulin pumps occur in more than a quarter of users but only occasionally result in device discontinuation, research shows.

Flash glucose monitoring technology

Browse new slide sets summarizing the latest results from real-world studies.

Podcasts

Interviews with experts on diabetes patient care